The 12 Hallmarks of Aging in Dogs, Explained
Read full insightPURR-001 for Cats: An Early Look at a Muscle-Loss Drug
What The Cat Health Company's 35-cat trial found, what's reportedly in the capsule, and what to do about muscle loss now.
As Seen On
Contents
PURR-001 at a glance
- What it is
- An investigational once-weekly capsule for age-related muscle loss in cats
- Developer
- The Cat Health Company, registered in Delaware with a subsidiary in Bucharest, Romania
- What's in it
- An mTOR inhibitor (reportedly low-dose rapamycin), mirtazapine and acarbose
- Evidence
- One 35-cat, 12-week, placebo-controlled trial, posted as a company preprint
- Headline result
- Body mass +7.40% vs +1.14% on placebo; back muscle +22.75% vs +9.00% (15 cats measured)
- Status
- Not authorized for sale anywhere
- When available
- No date announced
- Best step today
- A vet check, a muscle condition score and a look at diet
What the PURR-001 trial measured, and what it can't tell us
| What was measured | PURR-001 vs placebo | What it suggests | What it can't tell us |
|---|---|---|---|
| Body mass (27 cats) | +7.40% vs +1.14% | Treated cats gained more weight in 12 weeks | Whether the gain was muscle, fat or fluid |
| Back muscle height on ultrasound (15 cats) | +22.75% vs +9.00% | Treated cats' back muscles grew more | Whether strength, mobility or activity improved |
| Bloodwork at weeks 0, 6 and 12 | No treatment effect on any value | No sign of organ toxicity over 12 weeks | Rare or long-term side effects |
| Appetite and activity | Not formally measured | Owners reported increases anecdotally | How much of the gain came from eating more |
| Deaths over about a year | One treated cat, one placebo cat | Fewer than the roughly four expected at these ages | Whether a rare reaction played a part |
| Lifespan | Not measured | Not studied | Whether PURR-001 helps cats live longer |
Competitor label and pricing facts checked November 11, 2026. Sources are listed in the References section below.
Sources and further detail
- Bacita A, Duagi J, Marian I-C et al. (17 Aug 2026), *A randomized double-blind placebo-controlled clinical trial of a multi-target therapeutic against primary age-related feline sarcopenia: PURR-001* (preprint v1.0, not peer reviewed), Zenodo
- Longevity.Technology (18 Sept 2026), Cat sarcopenia drug moves toward market
- Longevity.Technology (8 Oct 2025), Cat Health Company secures $1.2m to extend feline healthspan
- The Cat Health Company, *Company website and team* (checked November 2026)
- The Underbite (18 Aug 2026), A feline muscle-loss drug clears its first trial
- Dechra Veterinary Products (label rev. January 2024), *Mirataz (mirtazapine transdermal ointment) prescribing information*, DailyMed
- Pye CR, Dowgray NJ, Eyre K et al. *Frontiers in Veterinary Science* (2026). Patterns of morbidity, multimorbidity, and mortality in aging cats: findings from seven years of the Cat Prospective Aging and Welfare Study
- Pye CR, Dowgray NJ, Eyre K et al. *Frontiers in Veterinary Science* (2025). Longitudinal changes in bodyweight, body condition, and muscle condition in aging pet cats
- Yau M. dvm360 (9 Apr 2025), Muscle condition scoring in cats
- World Small Animal Veterinary Association, *Global Nutrition Guidelines and toolkit* (checked November 2026)
- American Association of Feline Practitioners (2021), AAFP releases updated feline senior care guidelines
- Laflamme D, Gunn-Moore D. *Veterinary Clinics of North America: Small Animal Practice* (2014). Nutrition of aging cats
- Laflamme DP. *Veterinary Clinics of North America: Small Animal Practice* (2005). Nutrition for aging cats and dogs and the importance of body condition
- FDA (14 March 2025), FDA conditionally approves drug for management of ventricular hypertrophy in cats











